Related Experiment Video

Updated: Sep 30, 2026

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer
08:47

Rapid Viscoelastic Characterization of Airway Mucus Using a Benchtop Rheometer

Published on: April 21, 2022

[Mucolytics in acute and chronic respiratory tract disorders. II. Uses for treatment and antioxidant properties]

Maciej Kupczyk1, Piotr Kuna

  • 1Klinika Pneumonologii i Alergologii Instytutu Medycyny Wewnetrznej Akademii Medycznej w Łodzi.

Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego
|June 11, 2002
PubMed

Insights

Mucolytics like Ambroxol and N-acetylcysteine improve mucus clearance in respiratory diseases. These agents offer benefits in chronic obstructive pulmonary disease, asthma, and bronchitis, acting as adjunctive therapy.

Area of Science:

  • Pulmonology
  • Pharmacology

Context:

  • Mucus hypersecretion is a key factor in acute and chronic pulmonary diseases.
  • Effective management of respiratory tract disorders requires addressing mucus buildup.

Purpose:

  • To review the evidence supporting the use of mucolytic agents in respiratory disorders.
  • To highlight the efficacy and benefits of mucolytics as adjunctive therapy.

Summary:

  • Mucolytic agents, including Ambroxol and N-acetylcysteine, modify mucus secretion and physical properties, enhancing mucociliary clearance.
  • These drugs demonstrate effectiveness in chronic obstructive pulmonary disease, asthma, and acute bronchitis, offering modest improvements in symptoms and lung function.
  • Synergistic effects with antibiotics in chronic bronchitis exacerbations and antioxidant properties are noted. Ambroxol also inhibits allergic inflammation mediators.

Impact:

  • Mucolytics provide a cost-effective and well-tolerated therapeutic option for patients with various respiratory conditions.
  • Improved mucociliary clearance and symptom control can lead to better patient outcomes and quality of life.
  • The findings support the integration of mucolytics into standard treatment protocols for respiratory diseases.

More Related Videos

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

Related Concept Videos

Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...